Don Roberto says...

> Specifically, ALN-PCS administration resulted in a
> rapid, dose-dependent reduction in plasma PCSK9 of up to
> 84 percent relative to baseline and placebo, with a
> corresponding reduction in serum levels of low-density
> lipoprotein cholesterol (LDL-C) a clinically validated
> endpoint of up to 57 percent relative to baseline and
> placebo.

What exactly is a "clinically validated endpoint"?

Neither the Zetia class of cholesterol lowering drugs nor niacin
have shown significant reductions of cardiac events or all-cause
mortality despite their proven effects on cholesterol.

So in what sense is lowering LDL-C a clinically validated endpoint?